EXEL Exelixis, Inc.
Healthcare$49.98-0.34%ClosedMarket Cap: $12.56B
As of 2026-05-26
Valuation
P/E (TTM)
15.17
PEG
0.30
P/B
6.69
P/S
5.31
EV/EBITDA
12.56
DCF Value
$213.80
FCF Yield
7.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.4%
Operating Margin
39.4%
Net Margin
35.1%
ROE
40.2%
ROA
32.1%
ROIC
35.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $610.8M | 96.7% | $251.3M | $210.5M | $— | — |
| Q4 null | $598.7M | 95.6% | $235.2M | $244.5M | $— | — |
| FY null | $2.32B | 96.4% | $872.2M | $782.6M | $— | — |
| Q3 null | $597.8M | 96.9% | $236.5M | $193.6M | $— | — |
| Q2 null | $568.3M | 96.6% | $213.6M | $184.8M | $— | — |
| Q1 null | $555.4M | 96.5% | $186.9M | $159.6M | $— | — |
| FY null | $2.17B | 96.5% | $604.6M | $521.3M | $— | — |
| Q4 null | $566.8M | 96.5% | $163.2M | $139.9M | $— | — |
| Q3 null | $539.5M | 96.8% | $136.1M | $118.0M | $— | — |
| Q2 null | $637.2M | 97.2% | $275.9M | $226.1M | $— | — |
| Q1 null | $425.2M | 95.0% | $29.5M | $37.3M | $— | — |
| Q4 2023 | $479.7M | 95.5% | $81.8M | $85.5M | $0.27 | — |